Patients with locally advanced rectal cancer treated with FOLFOX before surgery had similar outcomes and side effect profiles to those treated with presurgical pelvic chemoradiation. Patients with ...
Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a median progression-free survival of 9.2 months. The study highlighted notable ...
Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized ...
Development of natural language processing (NLP) models for extracting key features from unstructured notes to create real-world data (RWD) assets for clinical research at scale. This is an ASCO ...
BARCELONA — The combination of standard FOLFOX chemotherapy with doublet immunotherapy did not improve progression-free survival compared with chemotherapy alone in patients with HER2-negative gastric ...
In a phase III trial, a chemotherapy regimen of fluorouracil, oxaliplatin, and docetaxel (TFOX) improved survival outcomes over standard FOLFOX for patients with advanced HER2-negative gastric cancer.
Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer. Among patients with BRAF V600E-mutant metastatic ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Meyerhardt is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results